Alnylam Pharmaceuticals, Inc. (ALNY) stock
ALNYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3047% below fair value
$156.50−3.23 (-2.02%)
Close on Nov 17, 2026Market cap $20.96BP/E 8.1Yield –
Alnylam Pharmaceuticals ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Alnylam Pharmaceuticals's ebitda for the twelve months ending Sep 30, 2026 was $1.03B, up 221.8% year over year. For fiscal 2025 it was $557.24M. The highest annual figure on record is $557.24M in fiscal 2025.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $557.24M | – |
| FY2024 | Dec 31, 2024 | -$120.22M | – |
| FY2023 | Dec 31, 2023 | -$228.12M | – |
| FY2022 | Dec 31, 2022 | -$740.60M | – |
| FY2021 | Dec 31, 2021 | -$661.09M | – |
| FY2020 | Dec 31, 2020 | -$793.67M | – |
| FY2019 | Dec 31, 2019 | -$922.26M | – |
| FY2018 | Dec 31, 2018 | -$799.43M | – |
| FY2017 | Dec 31, 2017 | -$488.19M | – |
| FY2016 | Dec 31, 2016 | -$409.46M | – |
| FY2015 | Dec 31, 2015 | -$276.96M | – |
| FY2014 | Dec 31, 2014 | -$393.05M | – |
| FY2013 | Dec 31, 2013 | -$82.71M | – |
| FY2012 | Dec 31, 2012 | -$120.42M | – |
| FY2011 | Dec 31, 2011 | -$49.69M | – |
| FY2010 | Dec 31, 2010 | -$39.13M | – |
| FY2009 | Dec 31, 2009 | -$42.12M | – |
| FY2008 | Dec 31, 2008 | -$22.11M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $360.27M | -5.6% |
| Q2 FY2026 | Jun 30, 2026 | $245.34M | – |
| Q1 FY2026 | Mar 31, 2026 | $282.19M | +768.8% |
| Q4 FY2025 | Dec 31, 2025 | $145.22M | – |
| Q3 FY2025 | Sep 30, 2025 | $381.79M | – |
| Q2 FY2025 | Jun 30, 2025 | -$2.26M | -103.5% |
| Q1 FY2025 | Mar 31, 2025 | $32.48M | – |
| Q4 FY2024 | Dec 31, 2024 | -$90.99M | – |
| Q3 FY2024 | Sep 30, 2024 | -$62.92M | -127.7% |
| Q2 FY2024 | Jun 30, 2024 | $63.62M | – |
| Q1 FY2024 | Mar 31, 2024 | -$29.92M | – |
| Q4 FY2023 | Dec 31, 2023 | -$102.92M | – |
| Q3 FY2023 | Sep 30, 2023 | $227.20M | – |
| Q2 FY2023 | Jun 30, 2023 | -$216.65M | – |
| Q1 FY2023 | Mar 31, 2023 | -$135.74M | – |
| Q4 FY2022 | Dec 31, 2022 | -$174.30M | – |
| Q3 FY2022 | Sep 30, 2022 | -$247.44M | – |
| Q2 FY2022 | Jun 30, 2022 | -$181.59M | – |
| Q1 FY2022 | Mar 31, 2022 | -$137.27M | – |
| Q4 FY2021 | Dec 31, 2021 | -$183.19M | – |
| Q3 FY2021 | Sep 30, 2021 | -$169.89M | – |
| Q2 FY2021 | Jun 30, 2021 | -$134.36M | – |
| Q1 FY2021 | Mar 31, 2021 | -$173.65M | – |
| Q4 FY2020 | Dec 31, 2020 | -$183.84M | – |
| Q3 FY2020 | Sep 30, 2020 | -$216.63M | – |
| Q2 FY2020 | Jun 30, 2020 | -$190.66M | – |
| Q1 FY2020 | Mar 31, 2020 | -$202.55M | – |
| Q4 FY2019 | Dec 31, 2019 | -$292.63M | – |
| Q3 FY2019 | Sep 30, 2019 | -$212.26M | – |
| Q2 FY2019 | Jun 30, 2019 | -$232.42M | – |
| Q1 FY2019 | Mar 31, 2019 | -$184.95M | – |
| Q4 FY2018 | Dec 31, 2018 | -$210.93M | – |
| Q3 FY2018 | Sep 30, 2018 | -$254.15M | – |
| Q2 FY2018 | Jun 30, 2018 | -$190.12M | – |
| Q1 FY2018 | Mar 31, 2018 | -$144.23M | – |
| Q4 FY2017 | Dec 31, 2017 | -$145.06M | – |
| Q3 FY2017 | Sep 30, 2017 | -$122.21M | – |
| Q2 FY2017 | Jun 30, 2017 | -$117.41M | – |
| Q1 FY2017 | Mar 31, 2017 | -$103.51M | – |
| Q4 FY2016 | Dec 31, 2016 | -$112.42M | – |
See a number that looks wrong?